A Study on the Incidence and Prevalence of 5q Spinal Muscular Atrophy in Canada Using Multiple Data Sources
OBJECTIVES: Spinal muscular atrophy (SMA) is a leading genetic cause of infant death and represents a significant burden of care. An improved understanding of the epidemiology of SMA in Canada may help inform strategies to improve the standard of care for individuals living with SMA.
METHODS: We employed a multisource approach to estimate the minimal incidence and prevalence of 5q SMA and to gain greater insight into recent clinical practices and treatment trends for the Canadian SMA population. Data sources included the Canadian Paediatric Surveillance Program (CPSP), Canadian Neuromuscular Disease Registry (CNDR), and molecular genetics laboratories in Canada.
RESULTS: The estimated annual minimum incidence of 5q SMA was 4.38, 3.44, and 7.99 cases per 100,000 live births in 2020 and 2021, based on CPSP, CNDR, and molecular genetics laboratories data, respectively, representing approximately 1 in 21,472 births (range 12,516-29,070) in Canada. SMA prevalence was estimated to be 0.85 per 100,000 persons aged 0-79 years. Delay in diagnosis exists across all SMA subtypes. Most common presenting symptoms were delayed milestones, hypotonia, and muscle weakness. Nusinersen was the most common disease-modifying treatment received. Most patients utilized multidisciplinary clinics for management of SMA.
CONCLUSION: This study provides data on the annual minimum incidence of pediatric 5q SMA in Canada. Recent therapeutic advances and newborn screening have the potential to drastically alter the natural history of SMA. Findings underline the importance of ongoing surveillance of the epidemiology and long-term health outcomes of SMA in the Canadian population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques - (2024) vom: 05. Jan., Seite 1-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Price, Tiffany R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical epidemiology |
|---|
| Anmerkungen: |
Date Revised 22.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1017/cjn.2024.1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366693433 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366693433 | ||
| 003 | DE-627 | ||
| 005 | 20240222232255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/cjn.2024.1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1302.xml |
| 035 | |a (DE-627)NLM366693433 | ||
| 035 | |a (NLM)38178730 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Price, Tiffany R |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Study on the Incidence and Prevalence of 5q Spinal Muscular Atrophy in Canada Using Multiple Data Sources |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a OBJECTIVES: Spinal muscular atrophy (SMA) is a leading genetic cause of infant death and represents a significant burden of care. An improved understanding of the epidemiology of SMA in Canada may help inform strategies to improve the standard of care for individuals living with SMA | ||
| 520 | |a METHODS: We employed a multisource approach to estimate the minimal incidence and prevalence of 5q SMA and to gain greater insight into recent clinical practices and treatment trends for the Canadian SMA population. Data sources included the Canadian Paediatric Surveillance Program (CPSP), Canadian Neuromuscular Disease Registry (CNDR), and molecular genetics laboratories in Canada | ||
| 520 | |a RESULTS: The estimated annual minimum incidence of 5q SMA was 4.38, 3.44, and 7.99 cases per 100,000 live births in 2020 and 2021, based on CPSP, CNDR, and molecular genetics laboratories data, respectively, representing approximately 1 in 21,472 births (range 12,516-29,070) in Canada. SMA prevalence was estimated to be 0.85 per 100,000 persons aged 0-79 years. Delay in diagnosis exists across all SMA subtypes. Most common presenting symptoms were delayed milestones, hypotonia, and muscle weakness. Nusinersen was the most common disease-modifying treatment received. Most patients utilized multidisciplinary clinics for management of SMA | ||
| 520 | |a CONCLUSION: This study provides data on the annual minimum incidence of pediatric 5q SMA in Canada. Recent therapeutic advances and newborn screening have the potential to drastically alter the natural history of SMA. Findings underline the importance of ongoing surveillance of the epidemiology and long-term health outcomes of SMA in the Canadian population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical epidemiology | |
| 650 | 4 | |a Minimum incidence | |
| 650 | 4 | |a Neuromuscular disease | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Spinal muscular atrophy | |
| 700 | 1 | |a Hodgkinson, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Westbury, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Korngut, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Innes, Micheil A |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Christian R |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Tanya N |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lijia |e verfasserin |4 aut | |
| 700 | 1 | |a Parboosingh, Jillian |e verfasserin |4 aut | |
| 700 | 1 | |a Mah, Jean K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques |d 1974 |g (2024) vom: 05. Jan., Seite 1-12 |w (DE-627)NLM00020014X |x 0317-1671 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:01 |g pages:1-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/cjn.2024.1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 01 |h 1-12 | ||